TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

Acta Biomedica Scientia

Volume 11, Issue 2, 2024
Mcmed International
Acta Biomedica Scientia
Issn
2348 - 215X (Print), 2348 - 2168 (Online)
Frequency
bi-annual
Email
editorabs@mcmed.us
Journal Home page
http://mcmed.us/journal/abs
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
EFFICACY OF LOW-DOSE PULSE CYCLOPHOSPHAMIDE IN THE MANAGEMENT OF SEVERE REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA: A PROSPECTIVE STUDY
Author
Dr. Neelu Mahendra Sunkavalli
Email
keyword
Autoimmune hemolyticanemia, Cyclophosphamide, Steroid-refractory AIHA, Immunosuppressive therapy, Hemolytic crisis
Abstract
Autoimmune hemolyticanemia (AIHA) is a rare condition characterized by the destruction of red blood cells due to autoantibodies. The management of severe, refractory AIHA remains challenging, particularly for patients who do not respond to steroids or other immunosuppressive therapies. This study evaluates the efficacy of low-dose pulse cyclophosphamide therapy (1g/month for four months) as an alternative to splenectomy and rituximab. A total of 34 patients (20 males, 14 females) aged 21–53 years were included. Hemoglobin levels significantly increased, and reticulocyte counts decreased following treatment. By the fourth cycle, 83% of patients achieved partial remission (PR), while 42% maintained hemoglobin levels ?10 g/dL without transfusion. Six months post-treatment, complete remission (CR) was observed in several cases. No severe adverse effects were reported. These findings suggest that low-dose pulse cyclophosphamide may be a promising and cost-effective option for refractory AIHA, warranting further large-scale studies
Download Broucher
Back to Top >>>>